Dapaglifozin (Lyndra Therapeutics)

N/A

Report date: 2024/06/12 15:33:21

Base Information

Drug NameDapaglifozin (Lyndra Therapeutics)
Drug Alias NameOral weekly dapagliflozin (Lyndra Therapeutics)Dapagliflozin (Lyndra Therapeutics)LYN‐045
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSodium/glucose cotransporter 2 inhibitors
TargetsSodium/glucose cotransporter 2
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesLyndra Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesLyndra Australia Pty Ltd
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 2

Other Information

ATC CodeN/A
Related LinksN/A